InvestorsHub Logo
Followers 0
Posts 18
Boards Moderated 0
Alias Born 08/10/2012

Re: None

Monday, 11/16/2015 7:23:24 AM

Monday, November 16, 2015 7:23:24 AM

Post# of 3067
ChromaDex Lead Ingredient NIAGEN® Nicotinamide Riboside Receives New Dietary Ingredient (NDI) Status From the FDA

IRVINE, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today it has received New Dietary Ingredient (NDI) status from the FDA for its patented and proprietary lead ingredient, NIAGEN® nicotinamide riboside.

ChromaDex's NIAGEN® is the first and only commercially available form of nicotinamide riboside NR and is supported by five patents issued and several pending, with patents rights acquired from Dartmouth College, Cornell University, and Washington University.

The Federal Food, Drug, and Cosmetic Act (the FD&C Act) requires that manufacturers and distributors who wish to market dietary supplements that contain "new dietary ingredients" notify the Food and Drug Administration about these ingredients. Generally, the notification must include information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing a new dietary ingredient will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. (See Section 413(d) of the FD&C Act, 21 U.S.C. 350b(d)).

Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “Receiving NDI status from the FDA validates the safety dossier we have compiled for NIAGEN®. Achieving NDI status is a significant milestone given that the FDA objected approximately 88% of NDI notifications in FY 2014. NDI status opens the door for the mainstream commercialization of NIAGEN® in dietary supplements.”

In August 2015, ChromaDex announced results from the first human clinical study which demonstrated that single doses of NIAGEN® nicotinamide riboside can elevate the co-enzyme NAD+ in the blood by as much as 2.7-fold and is safe.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDXC News